BSD Medical Reports Initiation of Clinical Study by University of Utah School of Medicine, Huntsman Cancer Center, Using MicroThermX® Microwave Ablation System to Treat Liver Tumors Business Wire SALT LAKE CITY -- June 11, 2014 BSD Medical Corporation (NASDAQ:BSDM) (Company or BSD) (www.BSDMedical.com), a leading provider of medical systems that utilize heat therapy to treat cancer, announced initiation of a clinical study by the University of Utah School of Medicine using BSD’s MicroThermX^® Microwave Ablation System (MicroThermX) to treat liver tumors. The study is a prospective, non-randomized, single arm trial that involves 20 patients. The study objective is to clinically evaluate the size of the ablation zones produced in liver tissue by BSD’s patented Synchronous Wave Alignment™ technology developed for MicroThermX. Both cirrhotic and non-cirrhotic liver tissue will be evaluated in this clinical study. The study is open for patient enrollment at the University of Utah School of Medicine. The principal investigator for the study is Ryan O’Hara, M.D., Assistant Professor of Radiology, Chief, Department of Interventional Radiology, Director of Interventional Oncology, University of Utah School of Medicine, Huntsman Cancer Hospital. “This trial will allow us to study the effects of the Synchronous Wave Alignment technology in both cirrhotic and non-cirrhotic liver tissue, and to determine if there is a difference in how the energy is absorbed in the two types of tissue,” stated Dr. O’Hara. The MicroThermX ^ utilizes patented, innovative, Synchronous Wave Alignment technology developed by BSD to provide larger and more uniform zones of ablation across all tissue types during a single procedure. The University of Utah study will evaluate the ability of MicroThermX ^ to create larger heating zones, using multiple antennas, than achieved by other available microwave ablation systems. Simultaneously utilizing multiple antennas gives physicians the ability to create a large, contiguous zone of necrosis with large margins. Larger, hotter heating zones may also decrease the occurrence of inadequate treatment of larger tumors. About the MicroThermX Microwave Ablation System The MicroThermX is a compact, mobile, state-of-the-art proprietary system that includes a microwave generator, single-patient-use disposable antennas and a thermistor-based temperature monitoring system. The innovative design of the MicroThermX is the first of its kind that allows delivery of higher power levels using a single generator. The MicroThermX utilizes patented, innovative Synchronous Wave Alignment technology developed by BSD to provide a wide range of uniform ablation zones. The MicroThermX includes innovative, high-end disposables (SynchroWave antennas) that are used in each ablation treatment and will provide a significant ongoing revenue stream. The soft tissue (tumor) ablation world market potential is estimated to exceed $2.3 billion. The U.S. Food and Drug Administration (FDA) has granted the Company a 510(k) clearance to market the MicroThermX ^ for ablation of soft tissue. BSD has also received CE Marking for the MicroThermX System, which allows BSD to market MicroThermX in Europe. CE Marking is also recognized in many countries outside the EU, providing BSD the ability to market MicroThermX to a number of international markets. About BSD Medical Corporation BSD Medical Corporation develops, manufactures, markets and services systems to treat cancer and benign diseases using heat therapy delivered using focused microwave energy and radiofrequency (RF). BSD’s product lines include ablation and hyperthermia treatment systems. BSD’s microwave ablation system has been developed as a stand-alone therapy to ablate and destroy soft tissue. The Company has developed extensive intellectual property, multiple products in the market, and well established distribution in the United States, Europe and Asia. BSD’s hyperthermia cancer treatment systems, which have been in use for several years in the United States, Europe and Asia, are used to treat certain tumors with heat (hyperthermia) while increasing the effectiveness of other therapies such as radiation therapy. Certain of the Company’s products have received regulatory approvals in the United States, Europe, China and Taiwan. For further information visit BSD Medical's website at www.BSDMedical.com. Forward-Looking Statements Statements contained in this press release that are not historical facts, including statements relating to our 2014 plans, are forward-looking statements, as defined in the Private Securities Litigation Reform Act of 1995. All forward-looking statements are subject to risks and uncertainties detailed in the Company's filings with the Securities and Exchange Commission, including the market demand for our MicroThermX® products and the regulatory requirements we face. These forward-looking statements speak only as of the date on which such statements are made, and the Company undertakes no obligation to update such statements to reflect events or circumstances arising after such date, except as required by law. Contact: BSD Medical Corporation William Barth, 801-972-5555 Fax: 801-972-5930 firstname.lastname@example.org
Icahn Takes 8.48% Stake in Hertz; May Seek Talks, Board Seat
BSD Medical Reports Initiation of Clinical Study by University of Utah School of Medicine, Huntsman Cancer Center, Using
Press spacebar to pause and continue. Press esc to stop.